BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30841025)

  • 1. LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis.
    Yang T; Li H; Chen T; Ren H; Shi P; Chen M
    Mol Cells; 2019 Mar; 42(3):270-283. PubMed ID: 30841025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-142-3p/MALAT1 inhibits lung cancer progression through repressing β-catenin expression.
    Liu J; Tian W; Zhang W; Jia Y; Yang X; Wang Y; Zhang J
    Biomed Pharmacother; 2019 Jun; 114():108847. PubMed ID: 30970294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
    Huang Q; Xing S; Peng A; Yu Z
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. m
    Jin D; Guo J; Wu Y; Du J; Yang L; Wang X; Di W; Hu B; An J; Kong L; Pan L; Su G
    J Hematol Oncol; 2019 Dec; 12(1):135. PubMed ID: 31818312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
    Huang J; Lin C; Dong H; Piao Z; Jin C; Han H; Jin D
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):663-672. PubMed ID: 33030583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
    Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
    Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
    Tang Y; Xiao G; Chen Y; Deng Y
    Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long Noncoding RNA SNHG6 Promotes Proliferation and Inhibits Apoptosis in Non-small Cell Lung Cancer Cells by Regulating miR-490-3p/RSF1 Axis.
    Dong Z; Liu H; Zhao G
    Cancer Biother Radiopharm; 2020 Jun; 35(5):351-361. PubMed ID: 32202941
    [No Abstract]   [Full Text] [Related]  

  • 10. LncRNA MALAT1 accelerates non-small cell lung cancer progression via regulating miR-185-5p/MDM4 axis.
    Wang D; Zhang S; Zhao M; Chen F
    Cancer Med; 2020 Dec; 9(23):9138-9149. PubMed ID: 33146951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer.
    Tang Q; Zhou Q; Li J; Yang X; Wang R; Wang X; Xu M; Han L; Wu W; Wang S
    Carcinogenesis; 2023 Aug; 44(6):497-510. PubMed ID: 37144780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depletion of lncRNA MALAT1 inhibited sunitinib resistance through regulating miR-362-3p-mediated G3BP1 in renal cell carcinoma.
    Wang Z; Chang X; Zhu G; Gao X; Chang L
    Cell Cycle; 2020 Aug; 19(16):2054-2062. PubMed ID: 32663095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA H19 interacted with miR-130a-3p and miR-17-5p to modify radio-resistance and chemo-sensitivity of cardiac carcinoma cells.
    Jia J; Zhang X; Zhan D; Li J; Li Z; Li H; Qian J
    Cancer Med; 2019 Apr; 8(4):1604-1618. PubMed ID: 30843379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
    Wei S; Wang K; Huang X; Zhao Z; Zhao Z
    Int J Immunopathol Pharmacol; 2019; 33():2058738419859699. PubMed ID: 31240979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway.
    Cui Y; Zhang F; Zhu C; Geng L; Tian T; Liu H
    Oncotarget; 2017 Mar; 8(11):17785-17794. PubMed ID: 28147312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
    Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
    Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC.
    Li X; Zhang X; Yang C; Cui S; Shen Q; Xu S
    Cell Cycle; 2018; 17(14):1772-1783. PubMed ID: 30010468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
    Li Q; Wang Y; He J
    J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MALAT1 enhances gemcitabine resistance in non-small cell lung cancer cells by directly affecting miR-27a-5p/PBOV1 axis.
    Chen W; Tan X; Yang Q; Fang Z; Xu Y
    Cell Signal; 2022 Jun; 94():110326. PubMed ID: 35367362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis.
    Li S; Mei Z; Hu HB; Zhang X
    J Cell Physiol; 2018 Sep; 233(9):6679-6688. PubMed ID: 29215698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.